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Background
Our preclinical data have demonstrated that intraductal
administration of PLD decreases tumor volume, prevents
the development of new lesions, and eradicates pre-malig-
nant disease. We initiated a phase I study to determine the
feasibility, safety, and maximum tolerated dose of PLD
administered to women awaiting mastectomy.
Methods
Women 18 or older with a known breast cancer awaiting
a mastectomy were eligible. Neoadjuvant chemotherapy
was allowed. Women with T4 features, prior breast irradi-
ation, or procedures that in the opinion of the investigator
may have altered the breast ductal system were excluded.
Participants underwent nipple aspiration and ductal can-
nulation using a dose escalation schema. The first 3
women received 5 mL intraductal dextrose only. We deter-
mined serial doxorubicin and doxorubicinol concentra-
tions in plasma and nipple aspirate fluid using LC/MS/
MS. We injected blue dye into the treated duct just prior to
mastectomy and obtained tissue for pharmacokinetic and
biomarker analysis.
Results
From 02/06 to 09/08, 14 women entered the study, and
12 underwent study procedures successfully. We com-
pleted all dose levels up to 10 mg PLD per one duct with-
out serious adverse events or surgical delays.
Pharmacokinetic and representative histopathological
data will be presented.
Conclusion
Intraductal administration of PLD is feasible and can be
safely administered both in women with and without
prior chemotherapy awaiting mastectomy. Studies to eval-
uate other agents administered to one or more ducts are
required.
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